What is it about?
Immune-checkpoint inhibitors (ICI) help the patient's immune system to fight cancers. Unfortunately, this could also lead to immune adverse events (irAEs) against healthy organs, including the thyroid. The main clinical consequences could be tiredness, palpitations, weight loss up to more serious life-threatening forms. Since cancer patients undergoing immunotherapy can be particularly frail, it is important to anticipate and treat such endocrine and thyroid complications as early as possible.
Featured Image
Photo by National Cancer Institute on Unsplash
Why is it important?
In addition to confirming the data already present in the literature, our work has demonstrated for the first time how the thyroid irAEs are also characterized by a reduction of the gland volume estimated by the neck ultrasound, which therefore can represent a new tool, common and accessible, for the early identification of these types of thyroid disease.
Perspectives
Writing this article was a great pleasure as it has co-authors with whom I have long standing collaborations and reward my efforts. in fact, it pushes me closer to the medical research world, which I would like to keep enjoy to possibly deliver a better and better health solutions to my patients.
Armando Patrizio
Universita degli Studi di Pisa
Read the Original
This page is a summary of: Immune Checkpoint Inhibitor-induced Thyroid Disorders: A Single Center
Experience, Current Pharmaceutical Design, February 2023, Bentham Science Publishers,
DOI: 10.2174/1381612828666220518151509.
You can read the full text:
Contributors
The following have contributed to this page
